JGC
IOVA icon

J. Goldman & Co’s Iovance Biotherapeutics IOVA Stock Holding History

J. Goldman & Co’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-13,500
Closed -$61.4K – 406
2023
Q3 		$61.4K Buy
+13,500
New +$88.1K ﹤0.01% 337
2023
Q2 		– Sell
-651,664
Closed -$3.98M – 435
2023
Q1 		$3.98M Buy
+651,664
New +$4.5M 0.16% 163
2020
Q2 		– Sell
-45,205
Closed -$1.35M – 300
2020
Q1 		$1.35M Buy
+45,205
New +$1.2M 0.16% 126

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

J. Goldman & Co's IOVA Position: Q4 2023 in Review

J. Goldman & Co sold out of Iovance Biotherapeutics (IOVA) in Q4 2023, closing a stake of 13,500 shares — an estimated $61.4K sold.

J. Goldman & Co first reported a position in IOVA in Q1 2020 and held it in 3 quarters. The position peaked at $3.98M in Q1 2023. 236 funds tracked by Wall St. Rank hold IOVA as of Q4 2023.

  • J. Goldman & Co reported no remaining Iovance Biotherapeutics position as of Q4 2023 after selling out during the quarter.
  • J. Goldman & Co sold 13,500 Iovance Biotherapeutics shares in Q4 2023, an estimated $61.4K.
  • J. Goldman & Co first reported a position in Iovance Biotherapeutics in Q1 2020 and held it in 3 quarters.
  • J. Goldman & Co's Iovance Biotherapeutics position peaked at $3.98M in Q1 2023.
  • 236 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2023.

Based on J. Goldman & Co's 13F filing for Q4 2023, filed 14 Feb 2024.